Endo is ‘laser-focused’ on cutting debt but may weigh acquisitions

By Devika Patel

Knoxville, Tenn., Jan. 8 – Endo International plc is “laser-focused” on reducing its debt but the company has “some room” to consider potential bolt-on acquisitions.

“When you look at what we guided to for the last quarter for nine months, I think we had indicated that we’re at about $7.5 billion with respect to debt and I think we were at around, maybe, the high fours for leverage,” president and chief executive officer Paul Campanelli said at the JP Morgan 2018 healthcare conference in San Francisco on Monday.

“We’re going to have to navigate through some choppy waters, there’s no denying that, but in terms of what we need to do to invest on our R&D side, to invest in smart, potential bolt-on acquisitions, we do have capital again, I think we have some room to consider things.

“We’re always going to be laser-focused on reducing our debt,” Campanelli said.

Endo is a Dublin, Ireland-based specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.